Patents by Inventor Christopher B. Cooper

Christopher B. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240246327
    Abstract: In certain examples, methods and devices, such as a soft electronics device, involve or include a first layer and a second layer from among the plurality of immiscible polymer layers, with the first and second layers integrated with one another to form a multilayered self-healing laminate, characterized in that polymer material in the first layer and polymer material in the second layer are cooperatively capable of autonomously recovering from at least one of the first layer and second layer being misaligned.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 25, 2024
    Inventors: Christopher B. Cooper, Zhenan Bao, Samuel E. Root
  • Patent number: 11964949
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: April 23, 2024
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • Publication number: 20240034915
    Abstract: Underwater adhesive are provided that include a hydrophobic polymer backbone having periodically embedded dynamic bonding units, where the underwater adhesive has nanophase separation between a first phase of the hydrophobic polymer backbone and a second phase of the dynamic bonding units. The resulting nanophase-separated morphology has clusters of dynamically bonded groups that are protected from water by a surrounding matrix of hydrophobic polymer backbone. This enables a pressure sensitive underwater adhesive with advantages of: no curing needed, reusable, recyclable, and good adhesion strength.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 1, 2024
    Inventors: Christopher B. Cooper, Zhenan Bao, Tomoko Nogusa
  • Publication number: 20200148651
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Inventors: Christopher B. COOPER, Haihong HUANG, Dongfeng ZHANG, Nader FOTOUHI, Takushi KANEKO
  • Patent number: 10550092
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 4, 2020
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • Publication number: 20180179168
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: July 15, 2016
    Publication date: June 28, 2018
    Inventors: Christopher B. COOPER, Haihong HUANG, Dongfeng ZHANG, Nader FOTOUHI, Takushi KANEKO
  • Publication number: 20180113032
    Abstract: A flexible stretchable sensor, methods of use, and methods of forming the same are disclosed herein. In one implementation, the flexible stretchable sensor comprises a plurality of flexible and stretchable fibers in close proximity to one another, wherein each of the flexible fibers comprises a hollow electrically insulating elastomeric fiber at least partially filled with a flexible and stretchable conductive material and an electrical connector in electrical communication with the flexible and stretchable conductive material, wherein a change in an electrical parameter of at least one of the plurality of flexible and stretchable fibers is used to sense an event associated with the at least one of the plurality of flexible and stretchable fibers.
    Type: Application
    Filed: October 10, 2017
    Publication date: April 26, 2018
    Inventors: Michael D. Dickey, Christopher B. Cooper, Mohammad Rashed Khan
  • Publication number: 20140243327
    Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: Global Alliance for TB Drug Development
    Inventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
  • Patent number: 8716292
    Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Global Alliance for TB Drug Development
    Inventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
  • Patent number: 8148396
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robl
  • Publication number: 20120071472
    Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: June 28, 2011
    Publication date: March 22, 2012
    Applicants: Institute of Materia Medica, Global Alliance for TB Drug Development
    Inventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
  • Publication number: 20110077395
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein.
    Type: Application
    Filed: December 2, 2010
    Publication date: March 31, 2011
    Inventors: James J. Li, Lawrence G. Hamann, Zheming Ruan, Christopher B. Cooper, Shung C. Wu, Ligaya M. Simpkins, Haixia Wang, Akbar Nayeem, Stanley R. Krystek
  • Publication number: 20090275279
    Abstract: A solar engine, which is vertically aligned along an interior portion of a building, is heated by solar radiation. The solar engine includes a warm air chamber at an upper portion of the solar engine and a hollow core positioned below the warm air chamber. Habitable spaces are positioned around the outside of the core toward an exterior of the building. Solar radiation on the warm air chamber creates a high temperature zone in the warm air chamber that induces a stack effect in which air rises through the core due to the lower temperatures in the core, and results in a negative pressure in the core. Air enters at a lower portion of the building and is pulled through the core by the solar engine. If the windows on the outside of the habitable spaces are opened, the negative pressure in the core causes passive cross ventilation from the outside of the building through the habitable spaces and into the core, where the air rises to the warm air chamber and then out of the building.
    Type: Application
    Filed: May 4, 2008
    Publication date: November 5, 2009
    Applicant: SKIDMORE OWINGS & MERRILL LLP
    Inventors: NIcholas Holt, Christopher B. Cooper, Roger Eugene Frechette, III, William F. Baker, JR.
  • Patent number: 7579360
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: August 25, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robl
  • Publication number: 20090203668
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Application
    Filed: April 16, 2009
    Publication date: August 13, 2009
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robi
  • Patent number: 7459460
    Abstract: Trisubstituted heteroaromatic compounds having the structure are provided, wherein X is C or N; A and B are each independently CH or N, with the proviso that A and B cannot both be CH; R1 is Ar-L-; R2 is hydrogen or alkyl; or R1 and R2 can be joined together to form a 4- to 7-membered cycloheteroalkyl ring; R3 to R8, Ar and L are as defined herein. A method for using these compounds to treat diseases associated with abnormal bone or mineral homeostasis is also provided.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: December 2, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wu Yang, John K. Dickson, Christopher B. Cooper, Dharmpal S. Dodd, Zheming Ruan, Dora M. Schnur
  • Patent number: 7453917
    Abstract: A continuous wave laser based on the electronic I*(2P½)?I(2P 3/2) transition of atomic iodine at 1.315 microns from the NCl(a1?)+I(2P 3/2) energy transfer reaction using a transverse flow device having gas flow from an upstream subsonic combustor section through a converging-diverging supersonic slit nozzle to a downstream supersonic section and an intersecting optical resonator. Laser operation is achieved through the transformation of the gas phase chemical reagents, D2 (deuterium), F2 (fluorine), NF3 (nitrogen trifluoride), DCl (deuterium chloride) HI (hydrogen iodide) in the subsonic section and HN3 (hydrogen azide) in the supersonic section.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: November 18, 2008
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Christopher B. Cooper, Gerald C. Manke, Gordon D. Hager, Timothy J. Madden
  • Publication number: 20040192746
    Abstract: The invention provides compounds of formula 1 1
    Type: Application
    Filed: April 5, 2004
    Publication date: September 30, 2004
    Applicant: Pfizer Inc
    Inventors: Mark A. Sanner, Chris J. Helal, Christopher B. Cooper
  • Patent number: 6778453
    Abstract: A method for storing a temperature threshold in an integrated circuit includes measuring operating parameters of the integrated circuit versus temperature, calculating a maximum temperature at which the integrated circuit performance exceeds predetermined specifications and storing parameters corresponding to the maximum temperature in a comparison circuit in the integrated circuit by selectively blowing fusable devices in the comparison circuit. The fusable devices may be antifuses.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: August 17, 2004
    Assignee: Micron Technology, Inc.
    Inventors: Christopher B. Cooper, Ming-Bo Liu, Chris G. Martin, Troy A. Manning, Stephen L. Casper, Charles H. Dennison, Brian M. Shirley, Brian L. Brown, Shubneesh Batra
  • Patent number: 6720427
    Abstract: The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: April 13, 2004
    Assignee: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christopher B. Cooper